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Background. Systemic capillary leak syndrome (SCLS) is a rare disorder characterized by unexplained, recurrent episodes of
transient, abrupt increase in endothelial permeability, leading to severe hypotension, generalized edema, and hemoconcentration.
Case Report. We report the case of a patient suffering from systemic capillary leak syndrome and present a possible interpretation
of the pathophysiology of this condition. Besides the classical triad of hypotension, edema, and hemoconcentration, we recorded
increased levels of methemoglobin, an index of NO overproduction. We present a possible interpretation of the pathophysiology
of this condition based on the fast and complete reversal of symptoms after methylene blue administration (which opposes NO-
induced effects) and speculate that increased NO levels could be implicated in the pathophysiology of the capillary leak phase.Why
should an emergency physician be aware of this?The safety of this treatment and its fluid- and cathecolamine-sparing effect deserve
consideration and further research.
1. Introduction
Systemic capillary leak syndrome (SCLS) is a rare disorder
characterized by unexplained, recurrent episodes of tran-
sient, abrupt increase in endothelial permeability, leading
to severe hypotension, generalized edema, and hemocon-
centration [1]. Both etiology and pathogenesis are currently
unknown, and systematic research is clearly limited by the
rarity of the disease. Several hypotheses have been formu-
lated, but clear evidence is lacking to support any.
We describe the improvement of one patient with SCLS
in two occasions with acute IV administration of methylene
blue after failure of the medications commonly used in
this setting. We present a possible interpretation of the
pathophysiology of this response to therapy.
2. Case Presentation
In March 2013, a 56-year-old man, otherwise healthy, suf-
fered from a cold and low-grade fever and gradually devel-
oped oliguria and weight gain. The general practitioner
prescribed some biochemical tests, which resulted normal
except for serum albumin 3 g/dL and a monoclonal IgG/𝜅
peak. An empirical course of broad-spectrum antibiotic and
furosemide was started.
Ten days later, he developed massive peripheral edema,
bilateral pleural and pericardial effusion, and ascites. Body
temperature was normal, arterial blood pressure (ABP)
was 90/60, and heart rate was (HR) 120/min. Blood tests
showed albumin 2.3 g/dL, creatinine 1.4mg/dL, sodium
129mEq/L, hemoglobin (Hb) 22 g/dL, and hematocrit (Ht)
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Table 1: Time course of hemodynamic and laboratory parameters at baseline and during the second acute episode.
Time (hours) BL 0 +5 +13.5 +24.5∗ +36.5 +39.5 +47.5 +54.5 +61.5 +65.5
ABP (mmHg) 125/75 80/50 90/60 65/30 135/80 110/60 100/70 110/50 129/61 110/50 115/60
HR (1/min) 73 140 134 120 105 100 97 112 98 102 101
CVP (mmHg) — — — 2/−3 (−1) — 2/−3 (−1) — 16/7 (12) — 7/0 (4) 8/4 (6)
Hb (g/dL) 12.5 22.0 22.4 22.7 17.5 15.2 13.4 12 10.9 10.5 10.2
Ht (%) 37.1 67.1 68.2 69 53.4 46.5 41.2 36.9 33.5 32.3 31.5
Albumin (g/dL) 3.9 3.7 3.3 — 2.7 — 2.4 — — — —
Creatinine (mg/dL) 1 1.2 0.9 1.2 1.5 1.2
pH 7.4 7.4 7.4 7.4 7.35 7.4 7.46 7.46 7.46 7.47 7.43
BE (mmol/L) 1.1 −2.8 −0.8 −4 −0.9 4.9 8.2 9.8 11.4 12.1 10.1
HCO3 (mmol/L) 26.4 22.9 24.2 22.6 24 29.6 32.4 34.3 36.1 36.6 35
Lactate (mmol/L) 0.6 1.6 1.7 2.2 2 1.3 1.6 1.2 1 1.1 1.3
Na (mEq/L) 141 134 134 131 137 139 141 142 143 143 143
K (mEq/L) 3.7 4.3 4.6 5.6 4.2 3.7 3.8 3.4 3.3 3.5 4.1
MetHb (%) — 0.5 0.6 0.4 1.3 1.4 1.5 1.4 1.5 1.3 1.7
BL: baseline (3 months before the acute episode). First line refers to hours after admission. ∗Denotes methylene blue administration.
ABP: arterial blood pressure; HR: heart rate; CVP: central venous pressure; Hb: haemoglobin; Ht: hematocrit;MetHb:methaemoglobin; BE: base excess; HCO3:
bicarbonate; Na: sodium; K: potassium.
62%. Crystalloid loading was started, but despite a posi-
tive balance of about 7000mL over 12 hours, ABP kept
falling down to 70/40 and the patient became anuric. Nore-
pinephrine (NE) up to 0.2mcg/kg/min was then added,
with ABP only rising to 80/60. Despite the presence of
only tachycardia as a SIRS sign (WBC 11780/mm3, PaCO2
37 with RR 18/min, core body temperature 36.4∘C, HR
120/min), the case was interpreted as refractory septic shock
of unknown origin (cultures later resulted negative), and
empirical treatment with methylene blue (1.5mg/kg IV bolus
over 1 hour) was given. Soon after the end of the infusion,
ABP rose to 140/80, HR 75/min, diuresis restarted, and
norepinephrine was suspended in 2 hours. Renal function
improved and edema and effusions reduced. The patient was
discharged home with no therapy, whilst awaiting more tests.
In the following months he experienced two less severe
episodes, requiring admittance to a nephrology ward for
fatigue, hypotension, peripheral swelling, oliguria, hypoal-
buminemia, and hemoconcentration. During the course of
these admissions, a series of tests were run, showing normal
levels of complement and C1-esterase inhibitor, negative
cancer markers, no autoantibodies; immunoglobulin levels,
including IgE, were in the normal range. Absence of diarrhea
excluded a protein losing enteropathy. Renal biopsy yielded
no alterations, and brain MR excluded pituitary lesions.
Thyroid and adrenal functions were normal. Bone marrow
biopsy excluded malignancies. Subcutaneous fatty tissue
biopsy excluded systemic amyloidosis. POEMS syndrome
was excluded by the absence of any sign of polyneuropa-
thy. Determination of vascular endothelial growth factor
(VEGF) showed increased levels (1429 pg/mL—normal val-
ues <450 pg/mL).The recurrence of episodes of hypotension,
hypoalbuminemia, and hemoconcentration and the presence
of a monoclonal IgG/𝜅 peak led to the diagnosis of systemic
capillary leak syndrome: prophylactic treatment with theo-
phylline 300mg bid was started.
In October 2013, the patient again experienced symptoms
of a cold similar to those before the first admission. On
arrival to the hospital, he was hypotensive and tachycardic;
blood tests (Table 1) showed severe hemoconcentration with
normal albumin levels. He was oliguric and had periph-
eral edema. Again, SIRS was not present. Echocardiogra-
phy showed a pericardial effusion 18mm, with no sign of
tamponade, normal valves, hypertrophic left ventricle with
slightly reduced end-diastolic volume (70mL), and 60%
ejection fraction, normal diastolic pattern, TAPSE 20mm.
Inferior vena cava diameter was unmeasurable. Fluid load-
ing with crystalloids was started, but despite a positive
balance of 5500mL/12 h, ABP kept falling (Figure 1) and
urine output remained low. NE was started and rapidly
increased up to 0.2mcg/kg/min, with minimal response in
terms of ABP. ABG showed increasing levels of lactic acid
and methaemoglobin (Table 1). Organ failure was quanti-
fied, yielding a SOFA score of 8, only depending, however,
from complete failure of cardiocirculatory and renal system
(norepinephrine 0.2mcg/kg/min, anuria) with no sign of
compromise of any other organ (GCS 15, bilirubin 1.1, platelet
count 180000, PaO2 81mmHg at room air).
Given the lack of response to treatment, bearing in
mind the previous anecdotal response, methylene blue was
administered (1.5mg/kg IV bolus over 1 hour), and ABP
again rapidly rose to 135/90, allowing for NE termination 8
hours later. Urine output gradually increased, allowing for
the negativization of fluid balance and concurrent recovery
of renal function. Haemoglobin levels normalized over a 48-
hour period, while albumin remained low (Figure 1). The
patient was thereafter discharged home.
3. Discussion
We describe a case of SCLS that responded twice—one time
as a rescue for a suspected diagnosis of septic shock, while the
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Figure 1: (a) Time course of blood pressure, haemoglobin, and albumin levels during the acute episode and effects of therapeutic inter-
ventions. (b) Time course of methemoglobin during the acute episode. BL: baseline (3 months before the acute episode), Hb: haemoglobin
(% variation form baseline), Alb: albumin (% variation form baseline), ABP: mean arterial blood pressure (absolute value), and MetHb:
methaemoglobin (% variation form baseline).
second time intentionally to the administration of methylene
blue. In both episodes, the patient had hypotension (with
ongoing further reduction during the first 12 hours) and signs
of severe haemoconcentration (Hb and Ht about 70% higher
than his own baseline normal values) and needed significant
amount of NE, despite positive fluid balance of >5 liters in
12 h, in line with the well-known poor response to fluid and
vasoactive drugs of SCLS [1]. On the contrary, albumin con-
centration was not increased, and it further decreased during
the first hours, suggesting a shift towards the extracellular
space due to increased endothelial permeability. Accordingly,
transcapillary escape rate of radio-labeled albuminwas found
to be elevated [2] in similar cases. Organ perfusion was
inadequate, as highlighted by the reduced urinary output
and the increase of plasma lactic acid; however, the absence
of a profound metabolic acidosis and the only presence of
tachycardia as a sign of SIRS could have raised doubts on the
diagnosis of refractory septic shock.
Actual management of the acute shock phase in this
condition is based on support of vital functionswith IVfluids,
including colloids and vasopressors [3]. We avoided albu-
min administration as extravasation may lead to increased
interstitial colloid osmotic pressure, with further reduction of
circulating blood volume, and to reduced de novo synthesis
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[4]. Infusion of pentastarch or dextrans [5] which could
seal the negatively charged endothelial fenestrations [4],
were unavailable for clinical use in Italy. Echocardiographic
assessment showed signs of both hypovolemia (complete
collapse of the inferior vena cava) and loss of systemic
vascular resistance (hypotension despite preserved systolic
function, as indicated by the normal values of ejection
fraction and TAPSE). After about 13 hours of standard
treatment, we decided to administer methylene blue and
consequently observed the rapid reversal of hypotension, a
concomitant gradual reduction of Hb andHt back to baseline
levels, an increase in urine output, a negative fluid balance,
and resolution of edema. All these signs are compatible with
normalization of endothelial permeability. Albumin levels,
however, remained low, likely because the escaped molecules
only partially flow back into vessels and are degraded in
tissues [6], while the turnover rate for de novo synthesis can
take up to 20 days to restore normal values [7]. Meanwhile,
during the second episode, we observed a significant increase
of methaemoglobin levels.
Despite severe hypotension, the patient was awake and
cooperative; moreover, hypoxemia was not present ad admis-
sion, and the lung CT scan excluded pulmonary edema. Usu-
ally, during SCLS attacks, musculature and connective tissue
are the principal target sites of the extravasation of plasma,
while the lungs, brain, and kidneys seem to be infrequently
involved [8]; as such, we think that themeasurement vascular
permeability, such as the pulmonary vascular permeability
index derived by transpulmonary thermodilution [9], is of
limited help in this phase. However, it is quite common that
pulmonary edema develops during the recovery phase, as an
iatrogenic side effect of the huge amount of intravenous fluid
often administered. In this phase, we can speculate that the
availability of such an index might potentially be of help for
the evaluation of the effects of therapy.
This patient, as the majority of those described in series
and case reports, presented a monoclonal gammopathy [10]
and elevated VEGF levels [2]; many Clarkson’s disease cases
predominantly have IgG-𝜅 or IgA-𝜅 monoclonal gammopa-
thy [8]: both multiple myeloma and systemic amyloidosis
were excluded via abdominal wall fat pad and bone mar-
row biopsy. POEMS syndrome (polyneuropathy, organo-
megaly, endocrinopathy, monoclonal gammopathy, and skin
changes), which is almost always associated with IgG-𝜆 or
IgA-𝜆, was excluded by the absence of any sign of polyneu-
ropathy.
The patient was also in long-term treatment with theo-
phylline [11], a drug that increases intracellular cAMP levels.
Any possible pathophysiologic interpretation of the response
to methylene blue should take these findings into account.
In addition to its mitogenic effect, VEGF was shown to
increase endothelial permeability, in a process mediated by
a NO-dependent increase in cGMP levels [12], the main
modulator of increased vascular permeability. Moreover, IL-
2 might contribute to the pathogenesis of SCLS [1], based on
the fact that IL-2 therapy can develop a leakage syndrome
undistinguishable from SCLS [13]. Indeed, increased IL-2
expression was demonstrated on perivascular cells of symp-
tomatic cases of SCLS [14]. Nitric oxide (NO) was suggested
as themediator of IL-2-induced endothelial permeabilization
[15], and inhibition of NO synthesis resulted in reversal of
IL-2-induced leakage [16]. Hence, the NO system seems to
be a common pathway for both IL-2- and VEGF-mediated
endothelial permeabilization. The vascular effects of NO
are mainly mediated by the activation of soluble guanylate
cyclase (sGC), which leads to the synthesis of cGMP; the lat-
ter, in turn, acts on several targets eventually causing smooth
muscle relaxation [17] and increased endothelial permeability
[18]. cGMP-mediated signalling also contributes to vasopres-
sor hyporesponsiveness [19]. Instead, cAMP (increased by
theophylline) counteracts with this pathway, protecting the
basal barrier function [18].
The response to methylene blue supports the hypoth-
esis that increased NO levels could be implicated in the
pathophysiology of the acute capillary leak phase. Methylene
blue (3,7-bis(dimethylamino)-phenothiazin-5-ium chloride)
is generally used in the setting of methaemoglobinemia [20]
and proved effective in reversing hypotension and restoring
the response to vasoactive drugs inmany different conditions
characterized by increased levels of NO (sepsis, anaphylaxis,
severe burns, ischaemia-reperfusion injury and liver fail-
ure) [21–25]. Methylene blue opposes NO-induced effects
mainly by inhibition of sGC [26–30], ultimately reducing the
generation of cGMP. Acute methylene blue administration,
unlike drugs that increase intracellular cAMP levels (such as
theophylline), aims at decreasing cGMP levels to reduce the
severity of supposedly NO-mediated attacks.
Although multiple therapies were administered during
the clinical management of the patient, both times we
recorded a clear temporal relation between methylene blue
administration and reversal of the symptoms, leading us to
identify this treatment as the main cause for the change in
the clinical course. We did not report direct measures of
NO levels in the case we described. Indeed, NO has a very
short half-life [31].However, in septic populations, circulating
levels of methaemoglobin proved effective indicators of NO
overproduction [32]. Methaemoglobin is generated by the
reaction of haemoglobin with NO [33]. In the present case,
methaemoglobin levels increased up to 250% their baseline
value during the course of the episode. We observed a
delay from symptoms appearance and methaemoglobin rise:
methaemoglobin generation in the presence of elevated NO
may require up to several hours to occur in vitro [34]; under
in vivo conditions, this timemay even increase, depending on
plasma redox state.
At pharmacologic doses methylene blue is a reducing
agent via the NADPH-methemoglobin reductase pathway
[20]. Methylene blue, when injected intravenously as an anti-
dote, is reduced to leucomethylene blue, which then reduces
the heme group from methemoglobin to hemoglobin. How-
ever, when given in higher doses, methylene blue may
oxidize the ferrous iron of hemoglobin to ferric iron, thus
potentially resulting in methemoglobin production. How-
ever, the dose we administered in the present case is well
within the doses used in the setting of methaemoglobinemia
(1-2mg/kg, repeated up to twice if symptoms of hypoxia
fail to subside) [35], thus reducing the possibility that the
elevated methaemoglobin levels we recorded were generated
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by the methylene blue we administered. Elevated levels of
methaemoglobin persisted up to the last blood sample taken
in the ICU, likely after the effects of methylene blue ended;
however, this is not surprising as the elimination half-life of
methaemoglobin has been reported to be as high as 15–20
hours [36].
The main limit of the present investigation is its case-
report nature. However, the rarity of this condition makes
experimental studies difficult to plan, and the incomplete
understanding of the underlying mechanisms does not
allow for preclinical modeling. Moreover, the hemodynamic
response to methylene blue might have simply faced by
chance the natural course of the syndrome, which sponta-
neously reversed. However, the response we observed was
similar in two different occasions, and both times it occurred
soon after the administration of the drug.
SCLS is a rare yet potentially severe condition, often
difficult to recognize and diagnose upon initial presentation.
Current therapies are mainly supportive, and the condition is
still associated with a 10-year mortality rate of about 30% [1].
We report our experience with a treatment whose safety [37],
alongwith its fluid- and catecholamine-sparing effect deserve
consideration and further research.
Abbreviation List
ABP: Arterial blood pressure
cAMP: Cyclic adenosine monophosphate
cGMP: Cyclic guanosine monophosphate
Hb: Hemoglobin
HR: Heart rate
Ht: Hematocrit
NE: Norepinephrine
NO: Nitric oxide
SCLS: Systemic capillary leak syndrome
sGC: Soluble guanilate cyclase
VEGF: Vascular endothelial growth factor.
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